CRISPR Therapeutics AG (NASDAQ:CRSP) shares declined 6.75% on Tuesday after the company revealed plans to raise $350 million through a convertible senior notes offering. The gene-editing firm said it ...

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

CRISPR THERAPEUTICS ® standard character mark and design logo and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY ® and the CASGEVY logo are registered trademarks ...

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 17, Morgan Stanley increased its price target on CRISPR Therapeutics AG ...

The gene-editing company said it intends to offer the convertible senior notes due 2031 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The ...

CRISPR Therapeutics (NASDAQ:CRSP) used a fireside chat at TD Cowen’s 46th Annual Healthcare Conference to outline how the ...

Discover how CRISPR-based therapy could revolutionize HPAI treatment in poultry, offering farmers a lifesaving alternative to complete flock depopulation and preventing costly outbreaks.

Shares of Crispr Therapeutics were lower after the company said it would raise $350 million through a private offering of senior notes. The stock was down 7.3% at $54.49 in Tuesday morning trading.

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.